ArticleNeoplasia (New York, N.Y.)
The human p73 promoter: characterization and identification of functional E2F binding sites.
Article in Neoplasia (New York, N.Y.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 47 citations in OpenAlex.
- CDK8 Inhibition Increases E2F1 Transcriptional Activity and Promotes STAT3-Dependent Suppression of Mcl-1 in Triple-Negative Breast Cancer Cell Line MDA-MB-468.International journal of molecular sciences · 2026Article
- A novel TAp73-inhibitory compound counteracts stemness features of glioblastoma stem cells.Molecular oncology · 2025Article
- The p53 family member p73 in the regulation of cell stress response.Biology direct · 2021Review
- MCL1 binds and negatively regulates the transcriptional function of tumor suppressor p73.Cell death & disease · 2020Article
- NF-Y loss triggers p53 stabilization and apoptosis in HPV18-positive cells by affecting E6 transcription.Oncotarget · 2016Article
- Article
- Transcriptional regulation of the p73 gene by Nrf-2 and promoter CpG methylation in human breast cancer.Oncotarget · 2014Article
- TAp73 protein stability is controlled by histone deacetylase 1 via regulation of Hsp90 chaperone function.The Journal of biological chemistry · 2013Article
- DNA damage-specific control of cell death by cryptochrome in p53-mutant ras-transformed cells.Cancer research · 2013Article
- E2F1 confers anticancer drug resistance by targeting ABC transporter family members and Bcl-2 via the p73/DNp73-miR-205 circuitry.Cell cycle (Georgetown, Tex.) · 2012Article
- Article
- p73 in Cancer.Genes & cancer · 2011Article
- p73 as a pharmaceutical target for cancer therapy.Current pharmaceutical design · 2011Review
- Article
- Identification of a candidate alternative promoter region of the human Bcl2L11 (Bim) gene.BMC molecular biology · 2008Article
- p63 and p73 in human cancer: defining the network.Oncogene · 2007Review
- Recombinant adenoviral vectors can induce expression of p73 via the E4-orf6/7 protein.Journal of virology · 2006Article
- p73 induction after DNA damage is regulated by checkpoint kinases Chk1 and Chk2.Genes & development · 2004Article
- Developmental roles of p73 in Cajal-Retzius cells and cortical patterning.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2004Article
- DNA damage induces transcriptional activation of p73 by removing C-EBPalpha repression on E2F1.Nucleic acids research · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
p73, a member of the p53 family, is overexpressed in many cancers. To understand the mechanism(s) underlying this overexpression, we have undertaken a detailed characterization of the human p73 promoter. The promoter is strongly activated in cells expressing exogenous E2F1 and suppressed by exogenous Rb. At least three functional E2F binding sites, located immediately upstream of exon 1 (at -284, -155 and -132) mediate this induction. 5' serially deleted promoter constructs and constructs harboring mutated E2F sites were analyzed for their response to exogenously expressed E2F1 or Rb to establish functionality of these sites. Authenticity of E2F sites was further confirmed by electrophoretic mobility shift assay (EMSA) using E2F1/DP1 heterodimers synthesized in vitro, followed by competition assays with unlabeled wild-type or mutant oligonucleotides and supershift analysis using anti-E2F1 antibodies. In vivo binding of E2F1 to the p73 promoter was demonstrated using nuclear extracts prepared from E2F1-inducible Saos2 cells. The region conferring the highest promoter activity was found to reside between -113 to -217 of the p73 gene. Two of the three functional E2F sites (at -155 and -132) reside within this region. Our results suggest that regulation of p73 expression is primarily mediated through binding of E2F1 to target sites at -155 and -132.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.